1. Home
  2. SGRP vs RNTX Comparison

SGRP vs RNTX Comparison

Compare SGRP & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGRP
  • RNTX
  • Stock Information
  • Founded
  • SGRP 1967
  • RNTX 2001
  • Country
  • SGRP United States
  • RNTX United States
  • Employees
  • SGRP N/A
  • RNTX N/A
  • Industry
  • SGRP Business Services
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SGRP Consumer Discretionary
  • RNTX Health Care
  • Exchange
  • SGRP Nasdaq
  • RNTX Nasdaq
  • Market Cap
  • SGRP 28.2M
  • RNTX 26.5M
  • IPO Year
  • SGRP 1996
  • RNTX N/A
  • Fundamental
  • Price
  • SGRP $1.18
  • RNTX $1.35
  • Analyst Decision
  • SGRP
  • RNTX Hold
  • Analyst Count
  • SGRP 0
  • RNTX 1
  • Target Price
  • SGRP N/A
  • RNTX N/A
  • AVG Volume (30 Days)
  • SGRP 294.4K
  • RNTX 114.6K
  • Earning Date
  • SGRP 08-14-2025
  • RNTX 08-14-2025
  • Dividend Yield
  • SGRP N/A
  • RNTX N/A
  • EPS Growth
  • SGRP N/A
  • RNTX N/A
  • EPS
  • SGRP N/A
  • RNTX N/A
  • Revenue
  • SGRP $143,501,000.00
  • RNTX N/A
  • Revenue This Year
  • SGRP $7.22
  • RNTX N/A
  • Revenue Next Year
  • SGRP N/A
  • RNTX N/A
  • P/E Ratio
  • SGRP N/A
  • RNTX N/A
  • Revenue Growth
  • SGRP N/A
  • RNTX N/A
  • 52 Week Low
  • SGRP $0.91
  • RNTX $1.04
  • 52 Week High
  • SGRP $2.48
  • RNTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • SGRP 52.52
  • RNTX 55.32
  • Support Level
  • SGRP $1.14
  • RNTX $1.06
  • Resistance Level
  • SGRP $1.22
  • RNTX $1.48
  • Average True Range (ATR)
  • SGRP 0.07
  • RNTX 0.13
  • MACD
  • SGRP -0.00
  • RNTX 0.04
  • Stochastic Oscillator
  • SGRP 26.56
  • RNTX 68.72

About SGRP SPAR Group Inc.

SPAR Group Inc is a merchandising and brand marketing services company, providing a broad range of sales-enhancing services to retailers across classes of trade and consumer goods manufacturers and distributors. It also provides a range of services to retailers, consumer goods manufacturers and distributors around the globe. The company divides its operations into three reportable regional segments: Americas, which is comprised of United States, Canada, Brazil and Mexico; Asia-Pacific (APAC), which is comprised of Japan, China, and India; and Europe, Middle East and Africa (EMEA), which is comprised of South Africa. It generates maximum revenue from the Americas.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: